Taichu Biotech is a biotechnology R&D firm based in Shanghai that offers developability evaluation services for new drugs. Its core services include mechanism-of-action studies from molecular to organ levels, establishment of in vivo animal models (induced and transgenic), pharmacodynamics research, pharmacokinetics, and toxicology studies. The company is described in reporting as a new-drug developability evaluation service platform. Taichu recently completed a nearly ¥400 million Series A financing. The round was reported to be led by IDG Capital with participation from multiple institutional investors. Company filings list shareholders including Ma Jing (28.56%, RMB 800.00 thousand subscribed capital) and partnership investors with listed subscribed amounts of RMB 673.1944 thousand and RMB 320.098 thousand.

Total raised

$57M

Funding rounds

1

Latest round

Series A

Latest activity

May 2023